A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma

Lei Xu1,2*, Pengfei Yang1,2,3*, Wenjie Liang4*, Weihai Liu4, Weigen Wang5, Chen Luo1,2, Jing Wang1,2, Zhiyi Peng4**, Lei Xing6, Mi Huang7**, Shusen Zheng8**, Tianye Niu1,2,9

1. Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2. Institute of Translational Medicine, Zhejiang University, Hangzhou, Zhejiang, China
3. College of Biomedical Engineering &Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China
4. Department of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5. Department of Radiology, the First Hospital of Ninghai County Medical Centre, Ningbo, Zhejiang, China
6. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
7. Department of Radiation Oncology, Duke University Medical Center, Durham, USA
8. Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
9. Engineering Research Center of Cognitive Healthcare of Zhejiang Province

*: Both authors contribute equally.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.02.16; Accepted: 2019.06.14; Published: 2019.07.09

Abstract

Purpose: Accurate lymph node (LN) status evaluation for intrahepatic cholangiocarcinoma (ICC) patients is essential for surgical planning. This study aimed to develop and validate a prediction model for preoperative LN status evaluation in ICC patients.

Methods and Materials: A group of 106 ICC patients, who were diagnosed between April 2011 and February 2016, was used for prediction model training. Image features were extracted from T1-weighted contrast-enhanced MR images. A support vector machine (SVM) model was built by using the most LN status-related features, which were selected using the maximum relevance minimum redundancy (mRMR) algorithm. The mRMR method ranked each feature according to its relevance to the LN status and redundancy with other features. An SVM score was calculated for each patient to reflect the LN metastasis (LNM) probability from the SVM model. Finally, a combination nomogram was constructed by incorporating the SVM score and clinical features. An independent group of 42 patients who were diagnosed from March 2016 to November 2017 was used to validate the prediction models. The model performances were evaluated on discrimination, calibration, and clinical utility.

Results: The SVM model was constructed based on five selected image features. Significant differences were found between patients with LNM and non-LNM in SVM scores in both groups (the training group: 0.5466 (interquartile range (IQR), 0.4059-0.6985) vs. 0.3226 (IQR, 0.0527-0.4659), P<0.0001; the validation group: 0.5831 (IQR, 0.3641-0.8162) vs. 0.3101 (IQR, 0.1029-0.4661), P=0.0015). The combination nomogram based on the SVM score, the CA 19-9 level, and the MR-reported LNM factor showed better discrimination in separating patients with LNM and non-LNM, comparing to the SVM model alone (AUC: the training group: 0.842 vs. 0.788; the validation group: 0.870 vs. 0.787). Favorable clinical utility was observed using the decision curve analysis for the nomogram.

Conclusion: The nomogram, incorporating the SVM score, CA 19-9 level and the MR-reported LNM factor, provided an individualized LN status evaluation and helped clinicians guide the surgical decisions.

Key words: Radiomics, intrahepatic cholangiocarcinoma, lymph node metastasis
Introduction

For liver, intrahepatic cholangiocarcinoma (ICC) is the second common malignancy with steadily growing incidence rate, with 5%-56% 5-year survival rate worldwide [1, 2]. When diagnosed, about 35% of ICC patients suffer from synchronous lymph node (LN) metastases [1]. Lymph node metastasis (LNM) generally indicates a negative prognosis for patients with ICC [3, 4]. Accurate preoperative evaluation of LN status could provide crucial information for treatment strategy decisions, especially for lymph node dissection (LND). In current clinical practice, the preoperative LN status in ICC is evaluated mainly based on the morphological features of the lymph nodes by reviewing the medical images preoperatively (for example, size and morphology of lymph nodes, signal changes within lymph nodes, etc.) [5, 6]. The prediction accuracy of current LN status evaluation method is often unstable and unsatisfactory.

A common strategy to predict the LN status was developed based on histopathologic findings, such as tumor differentiation and lymphatic invasion. However, the predictors based on this strategy were only available postoperatively. A clinical model built upon the clinical factors including tumor size, pathological differentiation, and tumor boundary could achieve high sensitivity of 96.1%, but the achievable specificity and accuracy were quite low, with a value of 23.0% in specificity and 40.3% in accuracy [7]. The above clinical model was reported to be useful in predicting LN status in patients with ICC. Nevertheless, this method was also challenging to apply in clinical practice, because subjectivity may exist in determination of tumor size and tumor boundary, based on clinician’s experience and judgment. When the tumor volume was small, or when the tumor boundary was unclear, the situation became exacerbated, and the prediction accuracy could be questionable.

On the other hand, several image-based methods have been proposed [5, 6, 8-10]. Seo et al. used the standardized uptake value as the LNM image marker based on positron emission tomography (PET) images [9]. However, the high cost of PET scan limited the utility in clinical practice. Nanashima et al. developed an LN status prediction model by combining CT findings and serum carbohydrate antigen 19-9 level [5]. The CT findings were used as image markers, which defined by radiologists according to the node status of hepatoduodenal ligament, common hepatic artery, and para-aorta based on CT images. The model showed a higher prediction accuracy than previous models based on clinical features only, or medical images alone. However, the underlying geometry and texture features of medical images were not fully excavated in these models. A comprehensive model incorporating clinical features and image features is needed.

Radiomics refers to mining the underlying relationships between quantitative image features and pathophysiology characteristics and then developing predictive models for clinical outcomes, such as survival, distant metastases, and molecular characteristics classification [11-15]. The use of nomograms has been widely accepted as a reliable tool by incorporating quantitative risk factors for clinical events. Recently, several researchers have developed nomograms for preoperative LN status evaluation in colorectal cancer and bladder cancer by incorporating clinical features and image features [16-18]. These nomograms achieved desirable predictive accuracies. The related studies demonstrated the feasibility of using the radiomics method to evaluate the LN status for patients with ICC.

In this study, a support vector machine (SVM) model was developed by using the radiomics method for preoperative LN status evaluation in ICC patients. A nomogram was then constructed by combining the clinical features and LNM probability, which was calculated based on the SVM model with the radiomics features from the MR images. We then investigated the difference in prediction accuracies between the combination model and the SVM model.

Methods

Workflow

Figure 1 presents the workflow of this study. It includes two major parts: (i) imaging and segmentation; (ii) feature extraction and model construction. The specific descriptions for these two parts are provided in the next sections.

Patient Population

The institutional review board of the institution (First Affiliated Hospital, Zhejiang University School of Medicine) approved this study, and the requirement of written informed consent was waived. In this retrospective study, we reviewed clinical records and T1-weighted contrast-enhanced MR images of ICC patients undergoing partial hepatectomy and LND between April 2011 and November 2017. The clinical LN status was obtained based on the clinicopathologic analysis of each patient (X-M Z, a pathologist with more than 10 years of experience in cancer diagnosis). Supplementary Material I presents the patient inclusion-exclusion criteria and recruitment pathway. We divided the overall patient population into two independent independent
theranostics 2019, vol. 9, issue 18

sub-groups according to the diagnosis time. The first sub-group was used as the training group to test the robustness for image features and conduct the model constructing purpose. This training group consisted of 106 patients diagnosed between April 2011 and February 2016 (53 females and 53 females; 35 to 86 years of age). The second sub-group was used as the validation group to test the proposed model. The validation group involved 42 patients (13 females and 29 females; 40 to 80 years of age) diagnosed between March 2016 and November 2017. All patients underwent pre-treatment T1-weighted contrast-enhanced MRI scans in our institution, since the contrast agent (Gadopentetate dimeglumine) was paramagnetic, and the signal intensity within the tumor would be enhanced after the injection in the images. The tumor detection and characterization of tumor phenotype appeared to be improved compared with the un-enhanced MRI and contrast-enhanced CT. The MRI acquisition parameters are presented in Supplementary Material II.

Baseline clinical features were derived from medical records, including gender, age, cholelithiasis (with or without), hepatitis B (with or without), cirrhosis (with or without), primary hepatic lobe site (left or right) and number of the primary tumors (single or multiple). The serum carbohydrate antigen 19-9 (CA19-9) level (abnormal or normal) and serum carcinoembryonic antigen (CEA) level (abnormal or normal) were achieved with the threshold value of the former 37 u/ml, and the latter 5 ng/ml in our institution. All MR images were evaluated by two experienced abdomen radiologists, both of whom were blind to the actual clinicopathologic results. The definitions for hepatitis B, number of the primary tumors and the MR-reported LNM factor are provided in Supplementary Material III. The number of the primary tumors was used as a clinical predictive factor, which referred to the number of solid primary tumors for each patient. To justify the use of baseline clinical features of patients in the training and validation groups, we performed the demographic comparison for each clinical feature between the training group and validation group for patients with LNM and non-LNM, respectively.

**VOI Segmentation and Feature Extraction**

We used the ITK-SNAP software to perform a 3D volume of interest (VOI) manual segmentation [19]. When multiple tumors were present, the tumor with the largest diameter was used to analyze. The VOI was segmented by two experienced radiologists independently. Radiologist-1 had experience of 12 years in MR images interpretation, and Radiologist-2 had experience of 14 years in MR images interpretation. Radiologist-1 finished the segmentation of patients in the training group only (106 patients). Radiologist-2 finished the segmentation of the overall patient population including the training and validation groups (148 patients). We then obtained two feature sets for the training group (feature set-1 was extracted based on the VOI segmentation of Radiologist-1; feature set-2 from the VOI segmentation of Radiologist-2) and a feature set for the validation group (feature set-3 from the VOI segmentation of Radiologist-2). The feature set-1 was used to perform the model training task. The feature set-2 was used to test the robustness and reproducibility of radiomics features from feature set-1. The feature set-3 was used to evaluate the predictive power of the proposed model.

---

**Figure 1.** Workflow of this study. The letters k and n are used to number the patients.
Image preprocessing was applied before the feature extraction, including image resampling of the arterial phase contrast-enhanced MR images to a 1×1×1 mm³ voxel size, and image grey level normalization to a scale of 1 to 32. A total number of 491 image features was extracted for each patient based on the VOI. The feature set included histogram features (number=6), geometry features (number=8), gray level co-occurrence matrix features (number=22), grey-level run-length matrix features (number=13), grey-level size zone matrix features (number=13), neighborhood gray-tone difference matrix features (number=5), and wavelet-based texture features (number=424). These features could characterize intratumor heterogeneity, as well as the underlying tumor genotypes and protein structures [20-26]. Supplementary Material IV provides the specific descriptions for all the radiomics features. The feature extraction procedure was implemented in MATLAB V2017b (MathWorks, Natick, MA, USA).

Feature Selection and SVM Model Construction

To eliminate the differences in the value scales of the radiomics features, feature normalization was performed before feature selection. For features in the training group, each feature for a specific patient was subtracted by the mean value and divided by standard deviation value from this group. The same normalization method was applied to features in the validation group using the mean values and standard deviation values calculated based on the training group.

Due to the relatively low-dimensional patient sample size and high-dimensional feature size, we then performed feature selection process to select the most LN status-related features to construct an SVM model. Feature selection was performed including two steps. First, we tested the robustness and reproducibility of image features. Since the features were extracted based on the VOIs segmented by radiologists manually, we only used the features that were most robust against the manual segmentation among different radiologists [26]. The correlation coefficient for each feature was calculated between the feature set-1 (from Radiologist-1) and feature set-2 (from Radiologist-2) by using the Spearman rank correlation test. Features with correlation coefficients greater than 0.8 were regarded as robust features, since a correlation coefficient of 0.8 indicated a high correlation according to a rule of thumb [26, 27]. Second, we applied the maximum relevance minimum redundancy (mRMR) algorithm to assess the relevance and redundancy for each feature [28, 29]. The maximum-relevance selection was aimed to select features that had the maximal correlation to the actual LN status. The minimum-redundancy selection ensured that the selected features had the minimal redundancy among each other. By using the mRMR method, the features were ranked according to their relevance-redundancy indexes. The several top features with high-relevance and low-redundancy were used to construct the SVM model by a linear kernel. In addition, we tried several typical feature selection methods, including mRMR, least absolute shrinkage and selection operator (LASSO), Random Forest, Elastic Net, Wilcoxon, and Gini index [30-32]. A comparison of these methods was also performed.

To demonstrate the association between the selected features and the actual LN status, we performed univariate analysis and correlation test for each selected features in the training group. An SVM score was calculated by using the SVM model for each patient to reflect the LNM probability. The discrimination measured the capacity of prediction models in separating patients with LNM and non-LNM. The discriminative capability was measured using receiver operating characteristic (ROC) curve, area under the curve (AUC) and prediction accuracy. AUC had a range from 0.5 to 1.0 (0.5 means no discriminative ability and 1.0 means ideal discriminative ability). The AUC was reported with a 95% confidence interval (CI). The prediction accuracy was calculated based on a threshold from a Youden Index, which could classify the patients into the predicted LNM group and non-LNM group according to the SVM score [33, 34]. To estimate the prediction error and confidence interval for both groups, we further tested the proposed model using a 10000-iteration bootstrap analysis in both training and validation group [35]. For each repetition, we randomly selected a subset of 75% patients from the training group or the validation group (the training group: 80 patients; the validation group: 32 patients) and calculated the corresponding AUC.

Development and Validation of Combination Nomogram

Multivariable analysis was applied to combine the clinical features and the SVM score with multivariable logistic regression model [17, 36]. The clinical features involved gender, age, cholelithiasis status, hepatitis status, cirrhosis status, primary site, number of the primary tumors, CEA level, CA19-9 level, and the MR-reported LNM. Then, a nomogram (called combination nomogram) was generated based on the proposed multivariate model. An LNM probability defined as nomogram score was then calculated for each patient by using the developed combination nomogram. To detect the
multi-collinearity among variables in the combination nomogram, the collinearity diagnosis was conducted by calculating the variance inflation factor (VIF) for variables in the combination nomogram [36, 37]. The VIF was defined as a ratio of the variance of the model with more than two variables, divided by the variance of the model with the single variable. Variables with VIFs > 10 indicated severity multicollinearities [37]. The threshold for the nomogram score was determined and used to classify patients in the validation group. We tested the nomogram by using the overall group including the feature set-2 and feature set-3. In addition, the combination nomogram was also tested using the bootstrap method in both training and validation groups.

The model performances were evaluated in three aspects: discrimination, calibration and clinical utility [17, 24]. The discrimination performance was accessed by using ROC, AUC, and prediction accuracy. The calibration was detected by using the calibration curves accompanied by the Hosmer-Lemeshow test (H-L test). The calibration curves measured the consistency between the predicted LNM probability and the actual LNM probability. The H-L test accessed the goodness-of-fit of the prediction models [17, 38]. A significant statistic from the H-L test indicated the significant difference between the predicted LNM probability and the actual LNM probability, meaning that the model was poor fitting. For the test of the overall group, we used the Delong test to measure the differences in ROC curves between combination nomogram and the SVM model [39, 40].

The decision curve analysis was applied to measure the clinical utility of models [41, 42]. The horizontal axis of the decision curve indicates the threshold probability in the range of 0.0 to 1.0. The vertical axis shows the clinical net benefit values resulted from the prediction models against the threshold probability. The decision curves corresponding to the “treat-all plan” and the “treat-none plan” are plotted as references. The detailed descriptions of the clinical net benefit, the “treat-all plan” and the “treat-none plan” are provided in Supplementary Material V. A larger area under the decision curve suggested a better clinical utility.

**Statistical Analysis Procedure**

All statistical tests used in this study were executed on MedCalc Statistical Software V15.2.2 (MedCalc Software bvba, Ostend, Belgium) or R software V3.4.1 (R Core Team, Vienna, Austria). Univariate analysis for clinical features was implemented by using the Chi-square test or Mann-Whitney U test, as appropriate. The categorical variable was analyzed using the Chi-square test, such as gender, primary site, number of the primary tumors, CEA level, etc. The continuous variable was analyzed using the Mann-Whitney U test, including age and tumor size. The P < 0.05 in two-tailed analyses was defined as the statistical significance.

**Results**

**Clinical Features**

Table 1 listed the clinical features of patients in the training group and validation group. No statistically significant difference existed in LNM rate (P = 0.9210) between the two groups. The LNM rate was defined as the ratio between the number of patients with LNM and the number of patients involved in the certain group. The LNM rate was 44.34% in the training group, and 45.24% in the validation group. While a temporal interval existed between the training and validation groups, there were no significant differences in the baseline clinical features between the training group and the validation group neither for patients with LNM nor non-LNM, justifying their use as the training and validation groups. The detailed results of univariable association analysis were presented in Supplementary Material VI.

**Feature Selection and SVM Model Construction**

Among the 491 image features, 91 features were retained through the robustness and reproducibility test with correlation coefficients greater than 0.8 between the feature set-1 and feature set-2 by using the Spearman rank correlation test. The mRMR based feature selection was used to decrease the redundancy of the feature set and build the optimal subset of complementary predictive features. The five highest mRMR-ranked features were selected to build the SVM model. The calculation formula for the SVM model was provided in Supplementary Material VII. The selected features were HLHGCM_maxpr, LLH_GLCM_sosvh, HLL_GLCM_corrm, LLL_GLCM_depth and HLL_GLSZM_LGZE. Among the five features, three features of HLHGCM_maxpr, LLL_GLCM_depth, and HLL_GLSZM_LGZE showed significant correlation with the actual LN status and significant difference between the patients with LNM and non-LNM in the training group with P < 0.05. The univariate analysis and correlation analysis for the selected features were summarized in Table 2. By comparing the prediction performances of different feature selection methods, it was noticed that the mRMR method showed the optimal performance. The specific prediction performances of different methods are summarized in Supplementary Material VIII.
calculated by using the bootstrap analysis. The values were consistent with the AUC values (95% CI, 0.634-0.898) for the validation group, 0.698-0.862 for the training group, and 0.787±0.041). Histograms describing the distributions of AUCs from the bootstrap method for the SVM model were provided in Supplementary Material IX. By using the Youden Index in the training group, the thresholds for the SVM score were defined as 0.4915. By using this threshold, patients with SVM scores higher than 0.4915 were classified as synchronous LNM, while patients with scores lower than 0.4915 were classified as non-LNM. The prediction accuracy was 73.58% for the training group and 69.05% for the validation group. The ROC curves and scatter plots for the SVM score were presented in Figure 2.

**Development of Combination Nomogram**

In the multivariable analysis, we used the Akaike information criterion (AIC) and the independence analysis to select the optimal feature combination. A combination of the SVM score, CA 19-9 level, and the MR-reported LNM factor was finally selected. The detailed descriptions of the model construction procedure were provided in Supplementary Material X. By using the collinearity diagnosis, the VIFs for the SVM score, CA19-9 level, and the MR-reported LNM factor were less than 10. The ROC curves for the SVM score were presented in Figure 2.

The calculation formula for the combination nomogram was displayed in Figure 3. The calculation formula for the combination nomogram was provided in Supplementary Material VII.

**Validation and Evaluation of SVM Model**

Significant differences were observed in SVM scores between the patients with synchronous LNM and non-LNM in both groups (the training group: 0.5466 (interquartile range (IQR), 0.4059-0.6985) vs. 0.3226 (IQR, 0.5270-0.4659); P<0.0001; the validation group: 0.5831 (IQR, 0.3641-0.8162) vs. 0.3101 (IQR, 0.1029-0.4661), P=0.0015). The AUC value was 0.788 (95% CI, 0.698-0.862) for the training group, and 0.787 (95% CI, 0.634-0.898) for the validation group. These values were consistent with the AUC values calculated by using the 10,000 times bootstrap analysis in both training and validation groups (mean ± standard deviation; the training group: 0.788±0.027; the validation group: 0.787±0.041). Histograms describing the distributions of AUCs from the bootstrap method for the SVM model were provided in Supplementary Material IX.

**Table 1. Patients and preoperative clinical feature**

| Clinical features | Training group (n=106) | Validation group (n=42) | P | Validation group (n=106) | Validation group (n=42) | P |
|-------------------|------------------------|------------------------|---|------------------------|------------------------|---|
| LNM               | non-LNM                | non-LNM                |---| non-LNM                | non-LNM                |---|
| Age (Mean±SD)     | 58.02±10.54            | 55.93±12.71            | 0.4662 | 60.34±8.52           | 60.34±7.17            | 0.4662 |
| Range             | (55,77)                | (39, 86)               |---| (40, 80)              | (43, 76)              |---|
| Gender            | Male                   | Female                 | 0.8450 | Male                   | Female                 | 0.5547 |
|                  | 23                     | 24                     |---| 30                     | 29                     |---|
|                  | 30                     | 29                     |---| 5                      | 8                      |---|
|                  | 30                     | 29                     |---| 14                     | 15                     |---|
|                  | 30                     | 29                     |---| 0.6683                 | 0.2479                 |---|
|                  | Left                   | Right                  | 0.0013 | Number of the primary tumors | 0.1536                 |---|
|                  | 30                     | 17                     |---| Single                 | 0.0013                 |---|
|                  | 30                     | 17                     |---| Multiple               | 0.6179                 |---|
|                  | 30                     | 17                     |---| Hepatitis              | 0.7065                 |---|
|                  | 30                     | 17                     |---| Without                | 0.6673                 |---|
|                  | 30                     | 17                     |---| With                   | 0.6673                 |---|
|                  | 30                     | 17                     |---| Cirrhosis              | 0.6673                 |---|
|                  | 30                     | 17                     |---| Without                | 0.6673                 |---|
|                  | 30                     | 17                     |---| With                   | 0.6673                 |---|
|                  | 30                     | 17                     |---| Cholelithiasis         | 0.7030                 |---|
|                  | 30                     | 17                     |---| Without                | 0.7030                 |---|
|                  | 30                     | 17                     |---| With                   | 0.7030                 |---|
|                  | 30                     | 17                     |---| CA19-9                 | 0.0086                 |---|
|                  | 30                     | 17                     |---| Normal                 | 0.0339                 |---|
|                  | 30                     | 17                     |---| Abnormal               | 0.0415                 |---|
|                  | 30                     | 17                     |---| CEA                    | 0.0674                 |---|
|                  | 30                     | 17                     |---| Normal                 | 0.0674                 |---|
|                  | 30                     | 17                     |---| MR-reported LNM        | 0.0012                 |---|
|                  | Negative               | Positive               | 0.0251 | Negative               | Positive               |---|
|                  | 30                     | 17                     |---| 0.0251                 | 0.0251                 |---|
|                  | Positive               | 30                     |---| 0.0251                 | 0.0251                 |---|

Note: LNM, lymph node metastasis; CA19-9, serum carbohydrate antigen 19-9; CEA, serum carcinoembryonic antigen; SD, standard deviation.

**Table 2. Univariate analysis and correlation test for radiomics features used in the SVM model for the training group**

| Radiomics features | Training group (n=106) | P | Correlation coefficient |
|--------------------|------------------------|---|------------------------|
|                    | LNM                    | non-LNM                   |
| HLL_GLCM_maxpr     | 0.2854 (0.2651 to 0.3175) | 0.2665 (0.2425 to 0.2805) | 0.0164 | 0.2343 | 0.0156 |
| HLL_GLCM_sosvh     | 1.0462 (0.9128 to 1.1260) | 1.1206 (0.9829 to 1.1929) | 0.0963 | -0.1623 | 0.0965 |
| HLL_GLCM_corrm     | -0.0178 (-0.0212 to -0.0132) | -0.0146 (-0.0175 to -0.0115) | 0.0629 | -0.1815 | 0.0626 |
| LLL_GLCM_denth     | 2.7902 (2.7389 to 2.8908) | 2.9404 (2.8816 to 2.9863) | 0.0014 | -0.3112 | 0.0012 |
| HLL_GLCZM_LGZE     | -0.0013 (-0.0010 to 0.0014) | 0.0018 (0.0014 to 0.0023) | 0.0028 | 0.2920 | 0.0024 |

Note: The univariate analysis for radiomics features was applied by using the Mann-Whitney U test. The correlation between radiomics features and the LN status was applied by using the Spearman rank correlation test. All features were reported as median and 95% confidence interval.
Figure 2. The ROC curves of the SVM model in the training group (A) and the validation group (B). The scatter plots of the SVM scores in the training group (C) and the validation group (D). The blue markers indicate patients with synchronous LNM; the red markers indicate patients with non-LNM. The black horizontal line presents the threshold. Patients with SVM scores higher than 0.4915 are classified as LNM; patients with scores lower than 0.4915 are classified as non-LNM.

Figure 3. The combination nomogram, combining SVM score, CA 19-9 level, and the MR-reported LNM factor.

Validation and Evaluation of Combination Nomogram
Compared to patients with synchronous non-LNM, patients with synchronous LNM had higher nomogram scores (the training group: 0.5928 (IQR, 0.1422-1.6073) vs. -1.2560 (IQR, -2.2466- -0.1691), P<0.0001; the validation group: 0.5151 (IQR, -0.4691-1.0837) vs. -1.6298 (IQR, -2.2261- -0.3005), P<0.0001). The calibration curves demonstrated good consistency between the predicted LNM probability and the actual LNM probability for the combination nomogram in both training and validation groups. For the training group, a non-significant statistic (P=0.4650) of the H-L test suggested no significant deviation from an ideal fitting. The AUC value was 0.842 (95% CI, 0.758-0.906). For the validation group, a non-significant statistic of P=0.8578 and an AUC of 0.870 (95% CI, 0.730-0.953) were obtained. By using the bootstrap method, the AUC values were generally consistent with that calculated based on the two groups (mean ± standard deviation; the training group: 0.842±0.026; the validation group: 0.869±0.033). Histograms describing the distributions of AUCs from the bootstrap method for the combination nomogram were provided in Supplementary Material IX. Figure 4 displayed the ROC curves and scatter
plots for the nomogram score. The calibration curves for the combination nomogram were provided in Figure 5A-B.

The prediction accuracy for the nomogram was calculated based on the threshold for the nomogram score. By using the Youden Index in the training group, the optimal threshold of -0.8270 was selected in the ROC analysis. Patients with the nomogram scores greater than -0.8270 were predicted as synchronous LNM, while patients with scores lower than -0.8270 were predicted as non-LNM. The prediction accuracy was 72.64% for the training group and 78.57% for the validation group. The decision curves for the combination nomogram and the SVM model were used to evaluate the clinical utilities. In both training and validation groups, the combination nomogram (red) showed a higher area under decision curves than the SVM model (black) (Figure 5C-D). The specific performances of the combination nomogram, the SVM model and the MR-reported LNM factor in both groups were summarized in Table 3.

Overall Validation of the SVM Model and Combination Nomogram

The prediction models were developed based on training group segmented by Radiologist-1 (feature set-1). To test the robustness and deliverability of the prediction models, we further tested the SVM model, and the combination nomogram using the overall dataset segmented by Radiologist-2 (feature set-2 and feature set-3). The combination nomogram showed better performance (Accuracy, 74.32%; AUC, 0.846 (95% CI, 0.777-0.900); Sensitivity, 87.88%; Specificity, 60.98%) than the SVM model alone (Accuracy, 67.57%; AUC, 0.787 (95% CI, 0.713-0.850); Sensitivity, 56.06%; Specificity, 78.05%). Further, significant differences from Delong test suggested significant improvements in predictive performances between the combination nomogram and the SVM model ($P=0.0219$). The ROC curves of the combination nomogram and the SVM model for the overall group were shown in Figure 6.

Figure 4. The ROC curves of the combination nomogram in the training group (A) and the validation group (B). The scatter plots for the nomogram score in the training group (C) and the validation group (D). The blue markers indicate patients with synchronous LNM; the red markers indicate patients with non-LNM. The black horizontal line presents the threshold. Patients with nomogram scores higher than -0.8270 are classified as LNM; patients with scores lower than -0.8270 are classified as non-LNM.

Table 3. Performances of the SVM model, combination nomogram and MR-reported LNM

| Models          | Training group | Validation group |
|-----------------|----------------|------------------|
|                 | Accuracy       | AUC (95%CI)      | Sensitivity | Specificity | S. E. | Accuracy | AUC (95%CI) | Sensitivity | Specificity | S. E. |
| SVM score       | 73.58%         | 0.788 (0.698 - 0.862) | 65.96%      | 79.66%      | 0.0441 | 69.05%   | 0.787 (0.634 - 0.988) | 52.63%      | 91.30%      | 0.0695 |
| Combination model | 72.64%         | 0.842 (0.758 - 0.906) | 89.36%      | 57.63%      | 0.0387 | 78.57%   | 0.870 (0.730 - 0.953) | 89.47%      | 69.57%      | 0.0540 |
| MR-reported LNM | 66.04%         | 0.658 (0.560 - 0.748) | 63.83%      | 87.80%      | 0.0469 | 66.67%   | 0.673 (0.511 - 0.809) | 73.68%      | 60.87%      | 0.0735 |

Note: SVM, support vector machine; S.E., standard error; CI, confidence interval.
Discussion

We developed and validated a nomogram by using radiomics approach for LN status preoperative evaluation in this study. The combination nomogram was constructed by incorporating the SVM score from the radiomics method and two clinical features of CA19-9 level and the MR-reported LNM factor. SVM score was an LNM probability calculated from the SVM model, which was developed based on five selective image features. The combination nomogram outperformed the SVM model in both training and validation groups (the training group: 0.842 vs. 0.788; the validation group 0.870 vs. 0.787). Thus, the favorable preoperative LN status prediction power of the proposed non-invasive method made it a potential preoperative evaluation tool in clinical practice.

The manual process of tumor segmentation and the reproducibility of radiomics features are the most debatable aspects in the radiomics analysis. Subjectivity in the determination of tumor volume and tumor boundary would occur. The uncertainties in tumor segmentation adversely affect the reproducibility of radiomics features [43]. A recent study investigating the robustness and reproducibility of radiomics features in different MRI.
sequences suggested that radiomics features extracted from T1-weighted images should be used with care, and only those reproducible features should be selected in building a radiomics model [44]. In this study, all patients were scanned in the same MRI scanner with liver acceleration volume acquisition (LAVA) sequence. The tumor segmentations were performed by two radiologists independently. Furthermore, we tested the robustness and reproducibility of image features by using two feature sets extracted based on the segmentations of the two radiologists. The five selected features and the proposed SVM model were found to be robust against tumor segmentation.

Note that all the selected five image features used in the SVM model were wavelet features. These features were extracted from images decomposed by undecimated 3D wavelet transforms. The wavelet transformation was a multiscale image analysis method by splitting the 3D image data into different frequency components along three axes. Fine and coarse texture extracted from the wavelet decomposed images could further present the spatial heterogeneity at multiple scales within tumor regions [45]. By using the correlation analysis, three out of the five features showed significant correlation with the actual LN status with \( P < 0.05 \). The possible reason was that the wavelet features had underlying associations with clinicopathology and tumor lymphatic system invasion. This observation was consistent with previous studies which used wavelet-based features in the radiomics models [46-48]. Recently, a study developed a prediction model to preoperatively differentiate pathological grades in patients with pancreatic neuroendocrine tumors [46]. The prediction model was constructed using eight image features, and seven out of them were wavelet features. A radiomics study employed machine-learning methods to predict histologic subtypes for patients with lung cancer. Four out of five features included in the model were wavelet features [48]. These studies confirmed that wavelet features are important imaging biomarkers for predicting the phenotype of tumors because they are closely related to the biological behavior of tumors.

In this study, CA19-9 level was served as an independent marker in prognosis stratification in patients with ICC, which was consistent with the previous studies [49]. In 2001, Jiang et al. proposed a clinical feature based prognostic score to accurately predict the prognosis for patients with ICC regardless of resection status, in which CA 19-9 was the only laboratory marker. It was also used as an independent predictive factor in prognosis evaluation in ICC patients with partial excision. More importantly, a study reported that the CA 19-9 level was also associated with the tumor progression of ICC [50]. Two recent studies both reported that the preoperative abnormal level of CA 19-9 was valuable in preoperative LN status evaluation [51, 52]. Similarly, the CA19-9 level was used as an independent predictor in the combination nomogram in this study, which also could improve the predictive power of the SVM model.

The proposed preoperative LN status prediction model has potential in assisting clinicians in making the effective surgical decision for patients with ICC. Although a series of studies had reported that LNM was highly correlative to the prognosis of ICC, the benefit of lymph node dissection (LND) is still controversial [53, 54]. de Jong et al. found that among patients who underwent routine LND, patients with LNM showed a worse median survival [55]. Meng et al. revealed that LND only benefited a subset of patients with a moderate survival benefit of about five months [56]. LNM-related prognostic stratification is a significant clinical problem in the management of ICC patients. Accurate preoperative LN status evaluation represents a key step in individualized and precision treatment of ICC patients.

Our study still had several limitations. Firstly, the patient population was collected from a single institution retrospectively. A total of 106 patients was enrolled in the training group, and 42 patients in the validation group. To evaluate the sample size for the validation group, we performed a power analysis based on the LNM rates of the training dataset and the validation dataset. Normally, a power value greater than 0.8 suggests a sufficient sample size [57, 58]. Our estimated power value was 0.85 for the current study. Thus, the sample sizes for the training and the validation groups were sufficient, meaning that the result and conclusion of this study were statistically significant. In the future, we will test the proposed model with multi-center and larger sample size. Secondly, we did not incorporate genomic characteristics in this study. Recently, increased researches with gene markers had been proposed to detect LNM in patients with ICC, such as VEGF and EGFR [59]. Though it might be an interesting study to combine genomics and radiomics analysis, it has not yet been determined how to incorporate genomic characteristics, image features, and clinical features together. Thirdly, because the diffusion-weighted imaging (DWI) sequences were altered several times during the long-time span of the study, we used only T1-weighted arterial phase MR images to mitigate any possible adverse effect caused by the changes in the DWI sequences and enhance the stability and robustness of the predictive model.
Conclusions

This study developed and validated a combination nomogram for the LN status preoperative evaluation in ICC patients. The combination nomogram developed using SVM score, CA19-9 level, and the MR-reported LNM factor showed better prediction accuracy than the MR-reported LNM factor and the SVM model alone. The proposed model could be used for individualized LN status evaluation and would help clinicians guide the surgical decisions. Multi-institution retrospective and prospective validation studies should be implemented before the practical application in the future clinical surgical plan determination.

Abbreviations

ICC: intrahepatic cholangiocarcinoma; LNM: lymph node metastasis; SVM: support vector machine; mRMR: maximum relevance minimum redundancy; LASSO: least absolute shrinkage and selection operator; ROC: receiver operating characteristic; AUC: area under the curve; VOI: volume of interest; AIC: Akaike information criterion; IQR: interquartile range; VIF: variance inflation factor; LND: lymph node dissection; CEA: serum carcinoembryonic antigen; CA 19-9: serum carbohydrate antigen 19-9.

Supplementary Material

Supplementary information, figures and tables. http://www.thno.org/v09p5374s1.pdf

Acknowledgements

We thank the staff in the center of Cryo-Electron Microscopy (CCEM), Zhejiang University for his technical assistance.

Sources of Funding

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant No. LR16F010001, LY17H160010, LY17E05 0008), National High-tech R&D Program for Young Scientists by the Ministry of Science and Technology of China (Grant No. 2015AA020917), National Key Research Plan by the Ministry of Science and Technology of China (Grant No. 2016YFC0104507), Natural Science Foundation of China (NSFC Grant No. 81871351), Zhejiang Province 151 Talents Program, Zhejiang University Education Foundation ZJU-Stanford Collaboration Fund, the Opening Fund of Engineering Research Center of Cognitive Healthcare of Zhejiang Province.

Contributions

Conception and design: WL, SZ, TN.

Development of methodology: LX, PY, TN.

Analysis and interpretation of data: LX, PY, WL.

Writing, review, and/or revision of the manuscript: LX, PY, WL, WW, CL, JW, ZP, LX, MH, SZ, TN.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Mavros MN, Economopoulos KP, Alexiou VG, Pavlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014; 149: 565-74.
2. Aljiffry M, Abdullahah A, Walsh M, Pellekian K, Alwashy I, Moliniari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009; 208: 134-47.
3. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29: 3140-5.
4. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakannishi K, Kamachi H, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005; 29: 728-33.
5. Nanashima A, Sakamoto A, Hayashi T, Tobina S, Azaki M, Kuniizaki M, et al. Preoperative diagnosis of lymph node metastasis in biliary and pancreatic carcinomas: evaluation of the combination of multi-detector CT and serum CA 19-9 level. Dig Dis Sci. 2010; 55: 3617-25.
6. Noji T, Kondo S, Hijano S, Tanaka E, Suzuki O, Shichinohe T. Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg. 2008; 95: 92-6.
7. Chen Y, Zeng Z, Tang Z, Fan J, Zhou J, Jiang W, et al. Prediction of the lymph node status in patients with intrahepatic cholangiocarcinoma: analysis of 320 surgical cases. Front Oncol. 2011; 42: 1-6.
8. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003; 95: 634-5.
9. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008; 143: 769-77.
10. Songthamwat M, Chamadol N, Khuntikeo N, Thinkhamrop J, Koonmee S, Chaichaya N, et al. Evaluating a preoperative protocol that includes magnetic resonance imaging for lymph node metastasis in the Cholangiocarcinoma Screening and Care Program (CASCAP) in Thailand. World J Surg Oncol. 2017; 15: 176.
11. Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, et al. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017; 18: e266-73.
12. Lambin P, Leijenaar RT, Deist TM, Peerlings J, de Jong EE, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14: 749-62.
13. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granot P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48: 441-6.
14. Limkin E, Sun R, Dorcie L, Zacharaki E, Robert C, Reuzé S, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 2017; 28: 1191-206.
15. Verma V, Simone CB, Krishnan S, Lin SH, Yang J, Hahn SM. The rise of radiomics and implications for oncologic management. J Natl Cancer Inst. 2017; 109: djx055.
16. Wu S, Zheng J, Li Y, Yu H, Shi S, Xie W, et al. A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer. Clin Cancer Res. 2017; 23: 6904-11.
17. Huang Y, Liang C, He L, Tian J, Liang C, Chen X, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol. 2016; 34: 2157-64.
18. Wu S, Zheng J, Li Y, Wu Z, Shi S, Huang M, et al. Development and validation of an MRI-based radiomics signature for the preoperative prediction of lymph node metastasis in bladder cancer. ElBioMedicine. 2018; 34: 76-84.
19. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31: 1166-28.
20. Armadasun M, King R. Textural features corresponding to textural properties. IEEE Trans Syst Man Cybern. 1989; 19: 1264-74.

http://www.thno.org
21. Bocchino C, Carabellese A, Caruso T, Della Sala G, Ricart S, Spinella A. Use of gray value distribution of run lengths for texture analysis. Pattern Recognit Lett. 1990; 11: 415-9.

22. Dasarathy BV, Holder EB. Image characterizations based on joint gray level-run length distributions. Pattern Recognit Lett. 1991; 12: 497-502.

23. Galloway MM. Texture analysis using gray level run lengths. Comput Graph Image Process. 1975; 4: 172-9.

24. Halabi S, Sng EL, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232-7.

25. Thibault G, Fertil B, Navarro C, Pereira S, Levy N, Sequeria J, et al. Texture indices and gray level size zone matrix: application to cell nuclei classification. Pattern Recognition Inf Process. 2009; 14:5.

26. Wu J, Aguiler T, Shultz D, Gudur M, Rubin DL, Loo Jr BW, et al. Early-stage non-small cell lung cancer: quantitative imaging characteristics of 18F fluorodeoxyglucose PET/CT allow prediction of distant metastasis. Radiology. 2016; 281: 270-8.

27. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012; 24: 69-71.

28. Unler A, Murat A, Chinnam RB. mr2PSO: A maximum relevance minimum redundancy feature selection method based on swarm intelligence for support vector machine classification. Inf Sci. 2011; 181: 4625-41.

29. Yu L, Liu H. Efficient feature selection via analysis of relevance and redundancy. J Mach Learn Res. 2004; 5: 1205-24.

30. Cordier JP, Grossmann P, Hou Y, Velazquez ER, Leijenaar RT, Herrmann G, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol. 2015; 114: 345-50.

31. Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ. Machine learning methods for quantitative radiomic biomarkers. Sci Rep. 2015; 5: 13087.

32. Zhang B, He X, Ouyang F, Gu D, Dong Y, Zhang L, et al. Radiomic machine-learning classifiers for prognostic biomarkers of advanced nasopharyngeal cancer. Cancer Lett. 2017; 403: 21-7.

33. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47: 458-72.

34. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3: 32-5.

35. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985; 39: 783-91.

36. Wu Y, Xu L, Yang P, Lin N, Huang X, Pan WB, et al. Survival Prediction in high-grade osteosarcoma using radiomics of diagnostic computed tomography. ElbisMedicine. 2016; 34: 27-34.

37. O'Brien RM. A caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007; 41: 673-90.

38. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007; 35: 2052-6.

39. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-45.

40. Demler OV, Pencina MJ, D'Agostino RB Sr. Misuse of DeLong test to compare AUCs for nested models. Stat Med. 2012; 31: 2577-87.

41. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26: 565-74.

42. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016; 352: i6.

43. Polan DF, Brady SL, Kaufman RA. Tissue segmentation of computed tomography images using a Random Forest algorithm: a feasibility study. Phys Med Biol. 2016; 61: 6553-69.

44. Baußer B, Weiss K, Pinto DDS. Robustness and reproducibility of radiomics in magnetic resonance imaging: a phantom study. Invest Radiol. 2018; 54: 221-8.

45. Kassen A, Thornhill R. Texture analysis: a review of neurologic MR imaging applications. AJNR Am J Neuroradiol. 2010; 31: 809-16.

46. Liang W, Yang P, Huang R, Xu L, Wang J, Liu W, et al. A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res. 2019; 25: 584-94.

47. Wilson R, Devaraj A. Radiomics of pulmonary nodules and lung cancer. Transl Lung Cancer Res. 2017; 6: 86-91.

48. Wu W, Parmar C, Grossmann P, Quackenbush J, Lambin P, Bussink J, et al. Exploratory study to identify radiomics classifiers for lung cancer histology. Front Oncol. 2016; 6: 71.

49. Jiang W, Zeng Z, Tang Z, Fan J, Sun H, Zhou J, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol. 2011; 22: 1644-52.

50. Bergquist JR, Ivnicevs T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: a national cohort analysis. J Surg Oncol. 2016; 114: 475-86.

51. Yamada T, Nakamichi Y, Okamura K, Tsuikawa T, Nakamura T, Noji T, et al. Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol. 2018; 33: 1626-33.

52. Meng Z, Lin X, Zhu J, Han S, Chen Y. A nomogram to predict lymph node metastasis before resection in intrahepatic cholangiocarcinoma. J Surg Res. 2018; 226: 56-63.

53. Weber SM, Ribero D, O’Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB. 2015; 17: 669-80.

54. Adachi T, Eguchi S. Lymph node dissection for intrahepatic cholangiocarcinoma: a critical review of the literature to date. J Hepatobiliary Pancreat Sci. 2014; 21: 162-8.

55. Jong MCd, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29: 3140-5.

56. Vitale A, Moustafa M, Spolverato G, Cini F, Cillo U, Pawlik TM. Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2016; 113: 685-91.

57. Bock J. Power and Sample Size Calculations. New York, USA: Springer; 2001: 309.

58. Wei J, Yang G, Hao X, Gu D, Tan Y, Wang X, et al. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Eur Radiol. 2016; 26: 877-88.

59. Yoshihara D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasi S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008; 98: 418-25.